The roles of adoptive and active forms of immunotherapy in the cure of children suffering from acute lymphoid leukemia: a) underestimation of active immunotherapy benefit, b) its immunogenetic indications to select sensitive patients, hence prevent chemotherapy’s late effects

• Published in: Biomedicine & pharmacotherapy Vol. 55; no. 9; pp. 531 - 542
• Main Authors: Mathé, G., Amiel, J.L.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Paris Elsevier SAS 01.11.2001; Elsevier
• Subjects: active immunotherapy; adoptive immunotherapy; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Child; children’s acute lymphoid leukemia; Chronic Disease; Combined Modality Therapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Drug Resistance, Neoplasm; Humans; Immunotherapy, Active - adverse effects; Immunotherapy, Adoptive - adverse effects; intensive chemotherapy late effects; Leukemia, Lymphoid - drug therapy; Leukemia, Lymphoid - therapy; Medical sciences; Pharmacology. Drug treatments; Prognosis; result underestimation; result underestimation; children’s acute lymphoid leukemia; intensive chemotherapy late effects; active immunotherapy; adoptive immunotherapy; Antineoplastic agent; Human; Indication; Toxicity; Acute; Treatment efficiency; Malignant hemopathy; Active immunization; Prevention; Chemotherapy; Immunogenetics; Sensitivity resistance; Treatment; Lymphoproliferative syndrome; Immunotherapy; Secondary effect; Combined treatment; Acute lymphocytic leukemia; High dose; Child; Adoptive immunization

Children’s acute lymphoid leukemia (ALL) chemotherapy started in 1948 with antimetabolites combined with steroids. It was enriched in 1959 with vincristine and cyclophosphamide and, in 1970, with daunomycin. It induced more and more apparently what were called complete remissions, and prolonged more...